Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Aug 16;79(2):562-563.
doi: 10.1093/cid/ciae320.

Hepatitis B-CpG Vaccine Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders

Rachel K Russ  1 , Haley M Vandehei  2 , Maria I Golovkina  1 , Harshitha Mogallapalli  3 , Freddy Caldera  3 , Mary S Hayney  1
Affiliations
Clinical Trial

Hepatitis B-CpG Vaccine Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders

Rachel K Russ et al. Clin Infect Dis. .

Abstract

This prospective study enrolled healthcare workers (HCWs) who were nonresponders following at least 5 doses of aluminum-adjuvanted hepatitis B vaccine who received the 2-dose Heplisav-B (HepB-CpG) (Dynavax Technologies Corporation, Emeryville, CA) series. After 2 doses of HepB-CpG, 43/47 (91%) participants, and with 1 dose, 41/49 (84%) responded. HepB-CpG could be the preferred vaccine in HCW nonresponders. Clinical Trials Registration. Clinicaltrials.gov NCT04456504.

Keywords: healthcare workers; hepatitis B vaccine; hepatitis B vaccine-CpG adjuvant; nonresponders; seroprotections.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. Dr. Caldera has received research support from Novavax and Takeda Pharmaceuticals. He has been a consultant for Takeda, Arena Pharmaceuticals, GSK, and Celgene. Dr. Hayney received research support from Novavax and Takeda Pharmaceuticals. She has served as a consultant and speaker for GSK vaccines. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

Publication types

Associated data